Our CEO François-Thomas Michaud and Strategic development director Vincent Menard are pleased to be in Boston this week for the BIO convention. They are looking forward to meeting with international leaders of the biotech industry.
QUEBEC CITY, May 29, 2018 – Feldan Therapeutics, Inc. announced today the issuance of a new patent related to the refinement of the Feldan Shuttle platform. This technology, a peptide-based delivery method which allows the introduction of foreign proteins, peptides or genome-editing nucleases inside cells, is applicable to the development of new therapies. The United States Patent
Feldan Therapeutics’ Research Director, Dr. David Guay, will be attending TIDES: Oligonucleotides and Peptide Therapeutics Conference next week, May 7-10th at Hynes Convention Center in Boston. Come to chat with him and attend to his presentation on May 07th, 3:15 pm to learn more about the development of the Feldan Shuttle technology. https://lifesciences.knect365.com/tides/speakers/david-guay-phd#
Our CEO Francois-Thomas Michaud and Strategic Alliance Director, Vincent Ménard, MBA Ph.D. will be attending RESI2018 conference in Toronto, April 10th. Come and meet with them to discuss how Feldan Therapeutics could be a strong investment opportunity. http://www.resiconference.com/
QUÉBEC city, March 29, 2018 – CQDM is pleased to announce the selection of a new Quantum Leap project jointly with Feldan Therapeutics for a total amount of $1.2M. The funds will be used for further development of a breakthrough drug delivery technology, in collaboration with Professor Frédéric Calon from Laval University. CQDM’s support for this
Feldan Therapeutics will be attending the Innate Killer Summit from March 27 to 29 in San Diego, CA, USA. Come and meet with our Business Development Director Meriem Benchabane and one of our scientist, Mario Harvey. Discover the Feldan Shuttle, a protein-based technology platform that directly delivers proteins – such as nucleases or transcription factors – inside cells to
Combined Feldan Shuttle and Green Cross LabCell NK cell technologies will be used to develop hyperactive NK cell immunotherapies QUEBEC, Jan. 15, 2018 /CNW Telbec/ – Green Cross LabCell, involved in development of next generation biologics, and Feldan Therapeutics, focused on intracellular delivery of proteins, today announced a joint